Developer docs
API playgroundTry for free, no card

Search company profiles

Exscientia

Full company profile

uuid0002o6h

Namestring
Exscientia
Legal namestring
Exscientia plc
Websiteurl
exscientia.ai
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new small molecule drug candidates. Founded in 2012 in Oxford, UK, the company's core technology combines generative AI models, machine learning, deep learning, and predictive analytics to automate the design-make-test-learn cycle, integrating multi-omics patient sample data (genomics, transcriptomics, proteomics, metabolomics) with proprietary biological and chemical datasets. The proprietary platform (including the Centaur Chemist system) has generated eight differentiated clinical candidates and produced DSP-1181 — the first AI-designed drug to enter human clinical trials — advancing to Phase I in 12 months versus a typical 4+ year preclinical timeline. AI capability depth is evidenced by reported hit rate improvements from traditional ~2% to 22-46%.

The company operates exclusively as a B2B technology partner to major pharmaceutical companies via co-development agreements, with no direct-to-consumer or self-service distribution. Customers include Sanofi (strategic research collaboration worth up to $5.2 billion across up to 15 oncology and immunology candidates), Merck KGaA (three-program collaboration), Bristol Myers Squibb, Sumitomo Pharma, and the Bill & Melinda Gates Foundation (neglected tropical diseases). Revenue mechanics rely on upfront payments, R&D funding, milestone payments tied to IND filings and clinical/regulatory progress, and tiered royalties on net sales; pricing is not publicly disclosed.

Exscientia raised approximately £299 million in cumulative funding across multiple rounds including a $225 million Series C led by SoftBank Vision Fund in 2021. The company was acquired by Recursion Pharmaceuticals on November 20, 2024, in an all-share transaction valued at approximately $650 million, and now operates as a wholly-owned subsidiary of Recursion, with the combined entity headquartered in Salt Lake City, Utah while maintaining significant UK operations.

Short descriptiontext

Exscientia is an AI-native pharmatech company using generative AI and multi-omics data to design small molecule drug candidates, serving major pharmaceutical companies via co-development partnerships that generated eight clinical candidates and the first AI-designed drug in human trials.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, small molecule design, generative chemistry, computational drug discovery, pharmaceutical AI platform
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI-Driven Drug Discovery
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Strategic Research Collaborations
TypeLicensing Royalties
Description

Exscientia enters into strategic partnerships with pharmaceutical companies where it receives upfront cash payments, research funding, milestone payments upon achieving development milestones, and tiered royalties on net sales of any approved products. The Sanofi partnership exemplifies this model with $100M upfront and up to $5.2B in potential milestones plus royalties.

bioforward.org
2Milestone Payments
TypeTransaction Fee
Description

Revenue generated through achievement of specific development milestones including IND filings, clinical trial phases, regulatory approvals, and commercial launch milestones under partnership agreements.

einpresswire.com
3AI Platform Services
TypeProfessional Services
Description

Exscientia generates revenue through collaborations where partners access its AI platform capabilities for drug discovery programs, with compensation tied to program success and advancement.

via.tt.se
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Exscientia operates an end-to-end AI-driven drug discovery platform that uses generative AI, machine learning, and patient-derived multi-omics data to design, optimize, and advance small molecule drug candidates. The company enters strategic co-development partnerships with pharmaceutical companies such as Sanofi, Merck KGaA, Bristol Myers Squibb, and Sumitomo Pharma, leading drug design and lead optimization while partners fund preclinical and clinical development, manufacturing, and commercialization. Revenue is generated through upfront payments, development milestone payments, and tiered royalties on approved products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 12 months from project initiation to Phase I trials for OCD drug candidate (vs. typical 4+ years)
+2 more records
Product overview1 text field

Exscientia operated as an AI drug discovery company offering a unified AI-driven platform for pharmaceutical research. The company's platform leveraged generative AI and patient sample data to design and optimize small molecule drug candidates across oncology and immunology. Exscientia has generated eight differentiated clinical candidates using its platform, including DSP-1181 (first AI-designed drug in human trials), and maintained strategic collaborations with major pharmaceutical partners including Sanofi ($5.2 billion deal) and Merck KGaA. The company was acquired by Recursion Pharmaceuticals in November 2024.

Product and service1 record
1AI Drug Discovery Platform
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-11-20
Description

Recursion Pharmaceuticals completed acquisition of Exscientia on November 20, 2024, in an all-share transaction valued at approximately $650 million. Exscientia shareholders received 0.7729 Recursion shares per ordinary share. The combined entity is headquartered in Salt Lake City, Utah with significant UK presence.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-22
Description

Exscientia announced an expansion of its collaboration with the Bill & Melinda Gates Foundation to accelerate drug discovery for neglected tropical diseases such as malaria and tuberculosis. This partnership addresses diseases disproportionately affecting low-income populations.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Sanofi and Exscientia established a strategic research collaboration to develop up to 15 novel small molecule candidates across oncology and immunology. Under the agreement, Sanofi paid $100 million upfront with potential milestone payments reaching up to $5.2 billion in aggregate if all programs achieve milestones, plus tiered royalties on product sales. Exscientia leads drug design and lead optimization while Sanofi assumes responsibility for preclinical and clinical development, manufacturing, and commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Exscientia initiated a new collaboration with Merck KGaA covering three programs in undisclosed therapeutic areas. The company achieved its first milestone in the Sanofi partnership and continues to advance this collaboration.

5Bristol Myers Squibb
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Exscientia had a partnership with Bristol Myers Squibb involving a PKC-theta inhibitor program. BMS later removed this clinical program from its pipeline in October 2025.

fiercebiotech.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Exscientia partnered with Sumitomo Pharma to develop an OCD (obsessive-compulsive disorder) drug candidate. This collaboration demonstrated Exscientia's ability to move a compound from initiation to Phase I clinical trials in just 12 months of preclinical work, showcasing AI-accelerated drug discovery.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Verge applies AI to human multi-omic datasets for target discovery in neuroscience and rare disease, with a wholly-owned pipeline approach. Comparable to Exscientia's patient-data-integration thesis but more focused on upstream target identification.

TypeDirect peer
Description

XtalPi combines AI, quantum physics, and automated robotics for small-molecule and crystal-form drug discovery, with major partnerships including Pfizer. It is a direct peer targeting the same AI-driven pharma partnership market.

TypeDirect peer
Description

Insitro applies machine learning to predictive modeling of disease biology and drug response, integrating induced pluripotent stem cell-derived data with ML to identify targets and design therapeutics. It is one of the closest direct competitors to Exscientia in AI-native small-molecule drug discovery.

TypeOthers
Description

Owkin applies federated learning and AI to patient-derived data for drug discovery and clinical development, primarily in oncology. Thematically adjacent to Exscientia's multi-omics/patient-data approach but with a stronger focus on clinical trial optimization rather than de novo molecule design.

TypeDirect peer
Description

Atomwise applies convolutional neural networks (AtomNet) to structure-based small-molecule design and pursues a partnership-heavy model with pharma and agrochemical clients. Comparable to Exscientia in target customer and AI-first molecule design approach.

6Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed Isomorphic Labs applies DeepMind-derived AI to drug design and operates a partnership-driven model very similar to Exscientia's. It competes for the same large-pharma partnership mandates (Novartis, Eli Lilly) and represents the most capital-rich AI drug-discovery competitor.

TypeDirect peer
Description

Now Exscientia's parent company, Recursion is a direct peer operating an AI-driven drug discovery platform combining phenomics, automated wet labs, and BioHive-2 supercomputer to advance a wholly-owned pipeline across oncology and rare disease. Both target the same pharma partnership buyers with generative and predictive AI for small-molecule discovery.

TypeEmerging player
Description

Iambic (formerly Entos) develops a generative AI platform for small-molecule drug discovery combining physics-based simulation with neural network models. It is an emerging competitor with partial overlap in generative chemistry and a wholly-owned pipeline focus.

TypeDirect peer
Description

BenevolentAI combines AI-driven target identification with drug discovery and was recently merged into the combined Recursion/Exscientia entity. It is a direct peer in AI-augmented small-molecule discovery, particularly in inflammation and CNS targets.

TypeDirect peer
Description

Schrödinger operates a physics-based computational platform for molecular simulation and drug discovery, with both a software/SaaS offering and a co-owned therapeutic pipeline. It competes directly with Exscientia for pharma partnerships combining computational chemistry with generative design.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Exscientia

AI-Driven Drug Discoveryexscientia.ai

Exscientia is an AI-native pharmatech company using generative AI and multi-omics data to design small molecule drug candidates, serving major pharmaceutical companies via co-development partnerships that generated eight clinical candidates and the first AI-designed drug in human trials.

What Exscientia does

Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new small molecule drug candidates. Founded in 2012 in Oxford, UK, the company's core technology combines generative AI models, machine learning, deep learning, and predictive analytics to automate the design-make-test-learn cycle, integrating multi-omics patient sample data (genomics, transcriptomics, proteomics, metabolomics) with proprietary biological and chemical datasets. The proprietary platform (including the Centaur Chemist system) has generated eight differentiated clinical candidates and produced DSP-1181 — the first AI-designed drug to enter human clinical trials — advancing to Phase I in 12 months versus a typical 4+ year preclinical timeline. AI capability depth is evidenced by reported hit rate improvements from traditional ~2% to 22-46%.

The company operates exclusively as a B2B technology partner to major pharmaceutical companies via co-development agreements, with no direct-to-consumer or self-service distribution. Customers include Sanofi (strategic research collaboration worth up to $5.2 billion across up to 15 oncology and immunology candidates), Merck KGaA (three-program collaboration), Bristol Myers Squibb, Sumitomo Pharma, and the Bill & Melinda Gates Foundation (neglected tropical diseases). Revenue mechanics rely on upfront payments, R&D funding, milestone payments tied to IND filings and clinical/regulatory progress, and tiered royalties on net sales; pricing is not publicly disclosed.

Exscientia raised approximately £299 million in cumulative funding across multiple rounds including a $225 million Series C led by SoftBank Vision Fund in 2021. The company was acquired by Recursion Pharmaceuticals on November 20, 2024, in an all-share transaction valued at approximately $650 million, and now operates as a wholly-owned subsidiary of Recursion, with the combined entity headquartered in Salt Lake City, Utah while maintaining significant UK operations.

Exscientia firmographics

Firmographics
Name
Exscientia
Legal name
Exscientia plc
Website
https://exscientia.ai
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
11–50 employees
Short description
Exscientia is an AI-native pharmatech company using generative AI and multi-omics data to design small molecule drug candidates, serving major pharmaceutical companies via co-development partnerships that generated eight clinical candidates and the first AI-designed drug in human trials.
Ownership category
akta.pro rank

Exscientia industry classification

Industry
Product category
AI-Driven Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • AI drug discovery
  • Small molecule design
  • Generative chemistry
  • Computational drug discovery
  • Pharmaceutical AI platform

Where Exscientia is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Exscientia business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Strategic Research Collaborations: Exscientia enters into strategic partnerships with pharmaceutical companies where it receives upfront cash payments, research funding, milestone payments upon achieving development milestones, and tiered royalties on net sales of any approved products. The Sanofi partnership exemplifies this model with $100M upfront and up to $5.2B in potential milestones plus royalties.
  2. Milestone Payments: Revenue generated through achievement of specific development milestones including IND filings, clinical trial phases, regulatory approvals, and commercial launch milestones under partnership agreements.
  3. AI Platform Services: Exscientia generates revenue through collaborations where partners access its AI platform capabilities for drug discovery programs, with compensation tied to program success and advancement.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Exscientia product offering

Product offering

Core offering

Exscientia operates an end-to-end AI-driven drug discovery platform that uses generative AI, machine learning, and patient-derived multi-omics data to design, optimize, and advance small molecule drug candidates. The company enters strategic co-development partnerships with pharmaceutical companies such as Sanofi, Merck KGaA, Bristol Myers Squibb, and Sumitomo Pharma, leading drug design and lead optimization while partners fund preclinical and clinical development, manufacturing, and commercialization. Revenue is generated through upfront payments, development milestone payments, and tiered royalties on approved products.

Product overview

Exscientia operated as an AI drug discovery company offering a unified AI-driven platform for pharmaceutical research. The company's platform leveraged generative AI and patient sample data to design and optimize small molecule drug candidates across oncology and immunology. Exscientia has generated eight differentiated clinical candidates using its platform, including DSP-1181 (first AI-designed drug in human trials), and maintained strategic collaborations with major pharmaceutical partners including Sanofi ($5.2 billion deal) and Merck KGaA. The company was acquired by Recursion Pharmaceuticals in November 2024.

Differentiator

Problem solved

Functional benefit

Products and services

  • AI Drug Discovery Platform

Quantifiable outcome

  • 12 months from project initiation to Phase I trials for OCD drug candidate (vs. typical 4+ years)
  • +2 more outcomes

Companies that use Exscientia

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Exscientia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Exscientia partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship, core and minor.

  • Recursion PharmaceuticalsflagshipStrategic or Co-development Partner · 20 November 2024Recursion Pharmaceuticals completed acquisition of Exscientia on November 20, 2024, in an all-share transaction valued at approximately $650 million. Exscientia shareholders received 0.7729 Recursion shares per ordinary share. The combined entity is headquartered in Salt Lake City, Utah with significant UK presence.
  • Bill & Melinda Gates FoundationcoreStrategic or Co-development Partner · 22 April 2024Exscientia announced an expansion of its collaboration with the Bill & Melinda Gates Foundation to accelerate drug discovery for neglected tropical diseases such as malaria and tuberculosis. This partnership addresses diseases disproportionately affecting low-income populations.
  • SanofiflagshipStrategic or Co-development Partner · 1 January 2024Sanofi and Exscientia established a strategic research collaboration to develop up to 15 novel small molecule candidates across oncology and immunology. Under the agreement, Sanofi paid $100 million upfront with potential milestone payments reaching up to $5.2 billion in aggregate if all programs achieve milestones, plus tiered royalties on product sales. Exscientia leads drug design and lead optimization while Sanofi assumes responsibility for preclinical and clinical development, manufacturing, and commercialization.
  • Merck KGaAcoreStrategic or Co-development Partner · 1 January 2023Exscientia initiated a new collaboration with Merck KGaA covering three programs in undisclosed therapeutic areas. The company achieved its first milestone in the Sanofi partnership and continues to advance this collaboration.
  • Bristol Myers SquibbminorStrategic or Co-development Partner · 1 January 2023Exscientia had a partnership with Bristol Myers Squibb involving a PKC-theta inhibitor program. BMS later removed this clinical program from its pipeline in October 2025.
  • Sumitomo PharmacoreStrategic or Co-development Partner · 1 January 2020Exscientia partnered with Sumitomo Pharma to develop an OCD (obsessive-compulsive disorder) drug candidate. This collaboration demonstrated Exscientia's ability to move a compound from initiation to Phase I clinical trials in just 12 months of preclinical work, showcasing AI-accelerated drug discovery.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Exscientia competitors and assessment

Company assessment

Emerging players

  • Verge Genomics: Verge applies AI to human multi-omic datasets for target discovery in neuroscience and rare disease, with a wholly-owned pipeline approach. Comparable to Exscientia's patient-data-integration thesis but more focused on upstream target identification.
  • Iambic Therapeutics (formerly Entos): Iambic (formerly Entos) develops a generative AI platform for small-molecule drug discovery combining physics-based simulation with neural network models. It is an emerging competitor with partial overlap in generative chemistry and a wholly-owned pipeline focus.

Direct peers

  • XtalPi: XtalPi combines AI, quantum physics, and automated robotics for small-molecule and crystal-form drug discovery, with major partnerships including Pfizer. It is a direct peer targeting the same AI-driven pharma partnership market.
  • Insitro: Insitro applies machine learning to predictive modeling of disease biology and drug response, integrating induced pluripotent stem cell-derived data with ML to identify targets and design therapeutics. It is one of the closest direct competitors to Exscientia in AI-native small-molecule drug discovery.
  • Atomwise: Atomwise applies convolutional neural networks (AtomNet) to structure-based small-molecule design and pursues a partnership-heavy model with pharma and agrochemical clients. Comparable to Exscientia in target customer and AI-first molecule design approach.
  • Isomorphic Labs: Alphabet-backed Isomorphic Labs applies DeepMind-derived AI to drug design and operates a partnership-driven model very similar to Exscientia's. It competes for the same large-pharma partnership mandates (Novartis, Eli Lilly) and represents the most capital-rich AI drug-discovery competitor.
  • Recursion Pharmaceuticals: Now Exscientia's parent company, Recursion is a direct peer operating an AI-driven drug discovery platform combining phenomics, automated wet labs, and BioHive-2 supercomputer to advance a wholly-owned pipeline across oncology and rare disease. Both target the same pharma partnership buyers with generative and predictive AI for small-molecule discovery.
  • BenevolentAI: BenevolentAI combines AI-driven target identification with drug discovery and was recently merged into the combined Recursion/Exscientia entity. It is a direct peer in AI-augmented small-molecule discovery, particularly in inflammation and CNS targets.
  • Schrödinger: Schrödinger operates a physics-based computational platform for molecular simulation and drug discovery, with both a software/SaaS offering and a co-owned therapeutic pipeline. It competes directly with Exscientia for pharma partnerships combining computational chemistry with generative design.

Others

  • Owkin: Owkin applies federated learning and AI to patient-derived data for drug discovery and clinical development, primarily in oncology. Thematically adjacent to Exscientia's multi-omics/patient-data approach but with a stronger focus on clinical trial optimization rather than de novo molecule design.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Exscientia social profiles

Digital presence

Exscientia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Exscientia leadership team

Management profile

Number of profiles

Profiles11 records

Exscientia funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Exscientia M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exscientia

What does Exscientia do?

Exscientia operates an end-to-end AI-driven drug discovery platform that uses generative AI, machine learning, and patient-derived multi-omics data to design, optimize, and advance small molecule drug candidates. The company enters strategic co-development partnerships with pharmaceutical companies such as Sanofi, Merck KGaA, Bristol Myers Squibb, and Sumitomo Pharma, leading drug design and lead optimization while partners fund preclinical and clinical development, manufacturing, and commercialization. Revenue is generated through upfront payments, development milestone payments, and tiered royalties on approved products.

Is Exscientia a public or private company?

Exscientia is a private company. It is classified as corporate owned and is currently acquired.

When was Exscientia founded?

Exscientia was founded in 2012. It employs 11 to 50 people.

Where is Exscientia based?

Exscientia is headquartered in Oxford, United Kingdom, in the Europe region.

How does Exscientia make money?

Three revenue lines are on record. Strategic Research Collaborations are the primary driver. The others are milestone Payments and AI Platform Services.

Who are Exscientia's main competitors?

Emerging players on record are Verge Genomics and Iambic Therapeutics (formerly Entos). Direct peers are XtalPi, Insitro, Atomwise, Isomorphic Labs, Recursion Pharmaceuticals, BenevolentAI and Schrödinger. Owkin is listed as an others.

Does Exscientia have an API?

No public API is recorded for Exscientia.

What industry is Exscientia in?

Exscientia's product category is AI-Driven Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BCC ResearchAI Revolutionizes Topical Drug Delivery: From Early Adoption to 2026 AdvancesArtificial intelligence is transforming topical drug delivery by accelerating molecule design, formulation optimization, and clinical outcomes across the pharmaceutical and cosmeceutical sectors. Key developments include regulatory harmonization between the FDA and EMA, significant industry consolidations like the Recursion-Exscientia merger, and major infrastructure investments such as the NVIDIA-Eli Lilly partnership. These advancements are driving measurable efficiency gains, with AI-enabled platforms reducing development times and improving permeability prediction accuracy globally.WebProNewsAI Drug Discovery’s Moment of Truth: Early Wins Emerge, But Clinical Proof Remains ElusiveAn analysis of AI drug discovery highlights a disconnect between rapid advances in computational tools like protein structure prediction and the limited clinical success of AI-designed candidates. While companies such as Insilico Medicine, Recursion, and Exscientia are actively integrating these technologies into their pipelines with some promising mid-stage results, traditional attrition rates remain high. Industry experts emphasize that despite significant investment and market growth projections, AI has not yet fundamentally altered the core risks of target selection or toxicology that drive clinical failures.RdworldonlineAs AI floods drug discovery with designs, Twist uses DNA chips to tackle the wet-lab bottleneckTwist Bioscience reported Q2 revenue of $123.8 million, with therapeutics revenue up 49% to $40.4 million, driven by AI-designed antibody orders. The company expects adjusted EBITDA breakeven in fiscal Q4 2026, citing scale and operating leverage. It plans to add two DNA writers to increase capacity.Mexico Business NewsAI, Biomarkers and Drug DesignThis article explains how artificial intelligence is transforming cancer drug development by analyzing multi-omic data to identify biomarkers, design new drug candidates, and predict protein structures for precision oncology. Companies including Insilico Medicine, Recursion, and Exscientia are building AI-first drug discovery platforms, with Insilico reporting its AI-discovered candidate reached Phase II trials, while Takeda entered a partnership potentially worth up to $600 million. The article argues that while AI cannot cure cancer alone, it reduces biological uncertainty by enabling tissue-agnostic, biology-driven treatment approaches that match therapies to patients based on molecular profiles rather than tumor location.GlobeNewswireAI Drug Discovery Investment Surges to $2+ Billion as Technology Cuts Development Timelines by 70%, Driven by Breakthrough Clinical Success RatesA new BCC Research analysis reports that AI-driven drug discovery has attracted over $2 billion in recent investment, with AI technologies cutting development timelines by 70% (from 4-5 years to 12-18 months) and decreasing R&D costs by 30-40%. Major funding rounds include Generate: Biomedicines ($500M+), Exscientia ($500M+), and Kailera Therapeutics ($600M Series B), while Bayer has committed $1.6 billion to AI-enabled platforms. The United States accounts for 60% of global AI drug discovery investment, driven by breakthrough clinical success rates that have doubled regulatory approval probabilities from 10-15% to 20%.GlobeNewswireAI Drug Discovery Investment Surges to $2+ Billion as Technology Cuts Development Timelines by 70%, Driven by Breakthrough Clinical Success RatesAI-driven drug discovery has attracted over $2 billion in investment, with AI technologies cutting development timelines by 70% from 4-5 years to 12-18 months while doubling clinical success rates, according to BCC Research analysis. The United States accounts for 60% of global investment, with major funding rounds including Generate: Biomedicines ($500M+), Exscientia ($500M+), and Kailera Therapeutics ($600M Series B). Bayer's $1.6 billion investment strategy into AI-enabled platforms exemplifies how established pharmaceutical companies are integrating AI capabilities, though infrastructure gaps in emerging markets and GDPR compliance remain implementation challenges.BCC ResearchThe $500 Million Question: Is AI Finally Fixing Drug Discovery's Broken Economics?This article reports on how AI is fundamentally transforming pharmaceutical drug discovery by compressing development timelines from 4-5 years to 12-18 months while reducing R&D costs by 30-40% and doubling approval probabilities. Major investment is flowing into the sector, with the NIH committing approximately $500 million and private companies including Generate Biomedicines, Exscientia, Kailera Therapeutics, and Bayer collectively investing billions into AI-enabled drug development platforms. The U.S. currently accounts for 60% of global investment in this space, with AI-validated targets showing a 2.5x greater likelihood of progressing through clinical development.CMC MarketsRewriting the Economics of Drug Discovery with Ben TaylorIn an interview with Recursion (RXRX) CFO Ben Taylor, the company outlined how its AI-native approach to drug discovery has shortened its development timeline from the industry standard of 4-5 years to 17 months, while achieving 30-60% improvement in clinical trial enrollment speed. Recursion, which acquired peer company Exscientia in August 2024, generates revenue through milestone payments from major pharma partners including Roche, Bayer, and Sanofi, having already achieved over $500 million in milestones. The company positions itself as an alternative to traditional drug development rather than a competitor to other AI biotech firms, leveraging Nvidia-powered supercomputing and proprietary data assets to explore previously unreachable biological targets.CMC MarketsRewriting the Economics of Drug Discovery with Ben TaylorRecursion CFO Ben Taylor discussed how the company's AI-native approach to drug discovery has shortened the typical 4-5 year development timeline to 17 months, achieving 30-60% improvement in clinical trial enrollment speed. Recursion completed its acquisition of peer company Exscientia in August 2024, bringing together Exscientia's chemistry focus with Recursion's biology platform, and has secured partnerships with Sanofi, Roche, and Bayer generating over $500 million in milestones. The company, which houses over 40 petabytes of internal lab data and utilizes Nvidia-powered supercomputer BioHive-2, is leveraging AI to explore the approximately 90% of the human genome that remains unexplored by traditional pharmaceutical research.Simply Wall StAI Drug Discovery Stocks Retail Investors Are Watching After Claude ScienceAnthropic's launch of Claude Science has drawn fresh attention to AI-powered drug discovery stocks, with investors assessing which companies stand to benefit from increased pharma interest in AI tools for drug development. Three companies are highlighted: IDEAYA Biosciences, a precision oncology firm with partnerships across Roche, AstraZeneca and Gilead and a US$3.48 billion market cap; Personalis, a cancer genomics company generating US$64.5 million in revenue with US$150 million equity raise plans; and Exscientia, an Oxford-based AI drug design company with forecast revenue growth of 39.8% annually but carrying a high P/S multiple near 29.7x and a history of shareholder dilution.